Pharmacodynamic Comparison of Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function Genotype: a Validation Study in Patients With Stable Coronary Artery Disease
Phase of Trial: Phase IV
Latest Information Update: 28 Mar 2019
Price : $35 *
At a glance
- Drugs Prasugrel (Primary) ; Ticagrelor (Primary)
- Indications Coronary artery disease
- Focus Pharmacodynamics
- 21 Mar 2019 Status changed from recruiting to completed.
- 09 Jan 2019 Planned End Date changed from 1 Aug 2019 to 1 May 2020.
- 09 Jan 2019 Planned primary completion date changed from 1 Apr 2019 to 1 Jan 2020.